Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Redx Pharma plc. (1/22/18). "Press Release: Redx Pharma Appoints Chief Medical Officer Who Will Oversee Launch of Phase I Clinical Trial of New Cancer Drug".

Organisations Organisation Redx Pharma plc (AIM: REDX)
  Group Redx Pharma (Group)
  Organisation 2 Lytix Biopharma AS
Products Product RXC004 (Redx Pharma)
  Product 2 clinical research
Persons Person Saunders, Andrew (Redx Pharma 201801– CMO before Lytix Biopharma + Linden Oncology Ltd + Eli Lilly + Roche)
  Person 2 Ross, Iain (201704 Board Member at several UK firms before Silence Therapeutics + Allergy Therapeutics + Quadrant)
     


Redx Pharma Plc (LON:REDX) has appointed a chief medical officer ahead of the imminent launch of phase I clinical trials of its lead drug.

Dr Andrew Saunders has 25 years in the cancer field and was recruited from Lytix Biopharma, a Norwegian immuno-oncology firm, where he held the same role.

He will work with the research and development team at Redx, "fronting" the clinical development of RXC004.

This is a potentially potent small molecule drug called a porcupine inhibitor that targets Wnt pathway.

Chairman Iain Ross said he was "very pleased" to announce Saunders' appointment.

"He brings to the company a wealth of relevant experience and expertise in the clinical development of oncology drugs," Ross explained.

"This will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004 in the coming weeks.

"We are very excited by the potential of RXC004 to make a major difference in cancer treatment.

"We intend to progress RXC004 in the clinic both as a monotherapy and in combination with a checkpoint inhibitor. Therefore, we envisage that Andrew's recent experience in immuno-oncology combination trials will be particularly pertinent to the design and execution of future clinical trials with RXC004."

Porcupine inhibitors such as RXC004 are a new and potentially breakthrough method of fighting the killer disease.

They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Kill the stem cells and you have a chance of eradicating the disease completely.

Clinical trials of the new Redx drug commence in the "coming weeks".

   
Record changed: 2018-02-01

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for Redx Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top